Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 3
2008 4
2009 3
2010 5
2011 2
2012 4
2013 6
2014 3
2015 1
2016 6
2017 8
2018 4
2019 11
2020 4
2021 4
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

66 results
Results by year
Filters applied: . Clear all
Page 1
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, Cheng L, Montironi R. Lopez-Beltran A, et al. Among authors: blanca a. Cancers (Basel). 2021 Jan 3;13(1):131. doi: 10.3390/cancers13010131. Cancers (Basel). 2021. PMID: 33401585 Free PMC article. Review.
The Identification of Immunological Biomarkers in Kidney Cancers.
Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. Lopez-Beltran A, et al. Among authors: blanca a. Front Oncol. 2018 Nov 2;8:456. doi: 10.3389/fonc.2018.00456. eCollection 2018. Front Oncol. 2018. PMID: 30450335 Free PMC article. Review.
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers.
Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R. Lopez-Beltran A, et al. Among authors: blanca a. Expert Rev Mol Diagn. 2020 Feb;20(2):231-243. doi: 10.1080/14737159.2020.1699791. Epub 2019 Dec 11. Expert Rev Mol Diagn. 2020. PMID: 31795775 Review.
Tp53 and its potential therapeutic role as a target in bladder cancer.
Ciccarese C, Massari F, Blanca A, Tortora G, Montironi R, Cheng L, Scarpelli M, Raspollini MR, Vau N, Fonseca J, Lopez-Beltran A. Ciccarese C, et al. Among authors: blanca a. Expert Opin Ther Targets. 2017 Apr;21(4):401-414. doi: 10.1080/14728222.2017.1297798. Epub 2017 Mar 1. Expert Opin Ther Targets. 2017. PMID: 28281901 Review.
Pathology of renal cell carcinoma: an update.
Lopez-Beltran A, Cheng L, Vidal A, Scarpelli M, Kirkali Z, Blanca A, Montironi R. Lopez-Beltran A, et al. Among authors: blanca a. Anal Quant Cytopathol Histpathol. 2013 Apr;35(2):61-76. Anal Quant Cytopathol Histpathol. 2013. PMID: 23700715 Review.
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.
Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A. Massari F, et al. Among authors: blanca a. Immunotherapy. 2019 Dec;11(17):1507-1521. doi: 10.2217/imt-2019-0115. Epub 2019 Oct 30. Immunotherapy. 2019. PMID: 31663411 Review.
Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
Gomez-Gomez E, Moreno Sorribas S, Valero-Rosa J, Blanca A, Mesa J, Salguero J, Carrasco-Valiente J, López-Ruiz D, Anglada-Curado FJ. Gomez-Gomez E, et al. Among authors: blanca a. Diagnostics (Basel). 2021 Jul 26;11(8):1335. doi: 10.3390/diagnostics11081335. Diagnostics (Basel). 2021. PMID: 34441270 Free PMC article.
66 results